Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Artiva Biotherapeutics, Inc.
Trials need funding. See this company's dilution risk and cash position.
- Phase 2Recruiting
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Allogeneic NK Cells
Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs) +7
NCT06991114Enrollment90StartJul 2025Primary CompletionJan 2028est.CompletionJan 2029est. - Phase 1/2Completed
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
AB-101, Rituximab
Non Hodgkin Lymphoma
NCT04673617Enrollment45StartMar 2021Primary CompletionOct 2025CompletionOct 2025 - Phase 1/2Withdrawn
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
AB-201, Cyclophosphamide
Breast Cancer, Gastric Cancer +1
NCT05678205Enrollment0StartAug 2023est.Primary CompletionApr 2027est.CompletionApr 2027est. - Phase 1Active, not recruiting
AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
AB-101, Cyclophosphamide
Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV +2
NCT06265220Enrollment51StartApr 2024Primary CompletionAug 2027est.CompletionAug 2027est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 2 | Recruiting | Allogeneic NK Cells | NCT06991114 |
| Phase 1/2 | Completed | AB-101, Rituximab | NCT04673617 |
| Phase 1/2 | Withdrawn | AB-201, Cyclophosphamide | NCT05678205 |
| Phase 1 | Active, not recruiting | AB-101, Cyclophosphamide | NCT06265220 |